ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Significant Increase in Short Interest

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was the target of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 376,500 shares, an increase of 11.0% from the May 31st total of 339,100 shares. Based on an average daily volume of 151,000 shares, the days-to-cover ratio is currently 2.5 days.

Insiders Place Their Bets

In related news, COO Muthusamy Shanmugam sold 20,000 shares of ANI Pharmaceuticals stock in a transaction on Friday, June 21st. The shares were sold at an average price of $58.90, for a total transaction of $1,178,000.00. Following the transaction, the chief operating officer now owns 682,620 shares in the company, valued at approximately $40,206,318. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 20,000 shares of the firm’s stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $58.90, for a total transaction of $1,178,000.00. Following the sale, the chief operating officer now directly owns 682,620 shares of the company’s stock, valued at $40,206,318. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Nikhil Lalwani sold 16,669 shares of the company’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $66.10, for a total value of $1,101,820.90. Following the completion of the transaction, the chief executive officer now directly owns 377,505 shares of the company’s stock, valued at approximately $24,953,080.50. The disclosure for this sale can be found here. Insiders sold a total of 156,688 shares of company stock worth $10,063,863 over the last three months. 12.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ANIP. Pacer Advisors Inc. purchased a new stake in ANI Pharmaceuticals during the fourth quarter worth $41,000. AJOVista LLC purchased a new stake in shares of ANI Pharmaceuticals during the 4th quarter worth $58,000. SG Americas Securities LLC bought a new stake in ANI Pharmaceuticals during the first quarter valued at about $106,000. China Universal Asset Management Co. Ltd. grew its stake in ANI Pharmaceuticals by 361.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,367 shares of the specialty pharmaceutical company’s stock valued at $131,000 after purchasing an additional 1,854 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new position in ANI Pharmaceuticals in the fourth quarter worth about $132,000. 76.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ANIP has been the subject of a number of research analyst reports. Capital One Financial started coverage on ANI Pharmaceuticals in a research report on Friday, March 15th. They set an “overweight” rating and a $80.00 price objective for the company. HC Wainwright increased their target price on ANI Pharmaceuticals from $87.00 to $94.00 and gave the company a “buy” rating in a research report on Wednesday, June 26th. Finally, Guggenheim restated a “buy” rating and issued a $77.00 price target on shares of ANI Pharmaceuticals in a research report on Tuesday, April 23rd. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $82.75.

ANI Pharmaceuticals Trading Up 0.9 %

ANIP opened at $63.68 on Monday. The company has a quick ratio of 3.12, a current ratio of 3.95 and a debt-to-equity ratio of 0.63. The stock’s fifty day moving average is $64.22 and its two-hundred day moving average is $61.83. The company has a market capitalization of $1.34 billion, a P/E ratio of 39.80 and a beta of 0.81. ANI Pharmaceuticals has a 52 week low of $48.20 and a 52 week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, May 10th. The specialty pharmaceutical company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.79 by $0.16. ANI Pharmaceuticals had a return on equity of 17.15% and a net margin of 6.87%. The firm had revenue of $137.43 million for the quarter, compared to analyst estimates of $125.01 million. Analysts forecast that ANI Pharmaceuticals will post 3.32 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.